GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (FRA:BPXA) » Definitions » YoY Rev. per Sh. Growth

Bellicum Pharmaceuticals (FRA:BPXA) YoY Rev. per Sh. Growth : -9.09% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Bellicum Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2023 was -9.09%.

Bellicum Pharmaceuticals's Revenue per Share for the three months ended in Sep. 2023 was €0.03.


Bellicum Pharmaceuticals YoY Rev. per Sh. Growth Historical Data

The historical data trend for Bellicum Pharmaceuticals's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals YoY Rev. per Sh. Growth Chart

Bellicum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 400.00 460.00 -94.83 571.83 -90.36

Bellicum Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -92.09 -46.43 - - -9.09

Bellicum Pharmaceuticals YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Bellicum Pharmaceuticals's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2022 )
=(Revenue per Share (A: Dec. 2022 )-Revenue per Share (A: Dec. 2021 ))/ | Revenue per Share (A: Dec. 2021 ) |
=(0.046-0.477)/ | 0.477 |
=-90.36 %

Bellicum Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2023 )
=(Revenue per Share (Q: Sep. 2023 )-Revenue per Share (Q: Sep. 2022 )) / | Revenue per Share (Q: Sep. 2022 )) |
=(0.03-0.033)/ | 0.033 |
=-9.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellicum Pharmaceuticals YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellicum Pharmaceuticals (FRA:BPXA) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (FRA:BPXA) Headlines

No Headlines